Drugs / SNC-109 CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05868083 | Jun 2022 → May 2024 | glioblastoma | Shanghai Simnova Biotechnology Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNC-109 CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868083 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109” NCT05868083 ↗ |